Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enterobacterial Capsules with Lenvatinib and PD-1 in Liver Cancer
NCT06563934Phase 2Not yet recruiting
- Start
- Aug 2024
- Primary completion
- May 2026
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Progression-Free Survival at 1 year. Planned start Aug 2024; status: not yet recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06563934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563934.